Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company achieved a revenue of 793 million yuan in 2025, representing a year-on-year growth of 15.49%. The net profit attributable to the parent company was 144 million yuan, up by 31.49%, while the net profit excluding non-recurring items reached 118 million yuan, increasing by 55.80% [4][6]. - The company's internationalization strategy is yielding results, with overseas sales reaching 107 million yuan in the first three quarters of 2025, a year-on-year increase of 23.62%, and a remarkable growth of 63.97% in Q3 alone. This segment is expected to be a significant growth driver [4][5]. - Domestic demand is recovering, particularly in the functional pharmaceutical sector, benefiting from increased R&D investments from downstream industrial clients. The company is leveraging its technological advantages to achieve rapid growth in this area [4][5]. Financial Summary - Revenue projections for 2025, 2026, and 2027 are 793 million yuan, 923 million yuan, and 1.074 billion yuan, respectively, with expected growth rates of 15%, 16%, and 16% [6][8]. - The net profit attributable to the parent company is forecasted to be 144 million yuan, 171 million yuan, and 202 million yuan for the years 2025, 2026, and 2027, reflecting year-on-year growth of 31%, 19%, and 18% [6][8]. - The company is positioned as a leader in the domestic animal model market, with high barriers to entry in gene editing models, which supports its expansion into overseas markets and innovation initiatives [6].

Group 1 - The Hong Kong pharmaceutical industry outperformed the Hang Seng Index in February, with the Hang Seng Healthcare Index declining by 2.2%, which is less than the overall Hang Seng Index decline [1] - The central government has officially classified biomedicine as an emerging pillar industry, indicating strong future support for the biopharmaceutical sector [2] - The total amount of innovative drugs exported in January exceeded 33.2 billion RMB, approaching a quarter of the total for the entire year of 2025, reflecting increasing recognition of Chinese innovative drugs by overseas pharmaceutical companies [1] Group 2 - China National Pharmaceutical Group announced the acquisition of Haogiya Biotech, a pioneer in small nucleic acid fields, and granted Sanofi exclusive rights for the global development and commercialization of Rovafatinib, with potential payments up to 1.53 billion USD [3] - The company is expected to achieve double-digit growth in product sales revenue by 2025, bolstered by the acquisition and the successful licensing of Rovafatinib, which indicates strong recognition of its R&D capabilities by global industry leaders [3] - The CXO sector leaders, WuXi Biologics and WuXi AppTec, are also recommended due to their positive earnings forecasts for 2025 and strong demand for new projects, supported by the government's increasing backing for innovative drugs [3]

Core Viewpoint - The article discusses the development of a novel bispecific antibody-drug conjugate (B6ADC) targeting TROP2 and c-Met for the treatment of pancreatic cancer, highlighting its potential to overcome limitations of existing therapies and improve treatment outcomes [3][6][9]. Group 1: Research Findings - The study successfully developed B6ADC, a nanobody-based bispecific ADC that targets both TROP2 and c-Met, demonstrating excellent antitumor activity in pancreatic cancer and various solid tumor models [4][9]. - B6ADC exhibited strong cytotoxicity against multiple cancer cell lines expressing TROP2/c-Met in vitro and showed superior tumor suppression in vivo compared to single-target ADCs and their combinations, including approved drugs like Sacituzumab Govitecan and Teliso-V [6][9]. - Notably, B6ADC can eliminate large tumors with a single low dose of 2.2 mg/kg body weight [7][10]. Group 2: Implications for Treatment - The research presents B6ADC as a promising strategy for treating pancreatic cancer and other malignancies that express TROP2 and c-Met, enhancing selectivity for tumors with dual or weak antigen expression [9][10]. - The findings suggest that TROP2/c-Met is an ideal combination target in solid tumors, with B6ADC demonstrating broad antitumor efficacy and good safety profiles [10].

Group 1 - Pearl Holdings (01176) experienced a significant drop of over 33% during trading, currently down 25.64%, due to the inability of independent valuers and auditors to complete their valuation and audit work for the fiscal year 2025, affecting various financial aspects including investment properties and receivables [1] - Some gold stocks showed recovery, with Zijin Mining International (02259) up 6.89%, Lingbao Gold (03330) up 7.31%, and China Gold International (02099) up 2.59%, as the precious metals market rebounded after a sharp decline, with spot gold rising above $4,700 [1] - Paig BioPharma-B (02565) rose over 6% following the announcement of a strategic cooperation agreement with Shanghai Tengrui Pharmaceutical for the commercialization of its core product in mainland China [1] Group 2 - Crystal International (02232) saw a post-earnings decline of over 4%, currently down 2.03%, despite reporting revenues of $2.641 billion for the year ending December 31, 2025, a 6.95% increase year-on-year, and a profit attributable to shareholders of $225 million, up 12.05% [2] - Oil and gas stocks fell sharply, with Shandong Molong (00568) down 4.49% and Sinopec Oilfield Service (01033) down 4.81%, as international oil prices dropped sharply, with Brent crude down 3% to $100 [2] Group 3 - China Duty Free Group (01880) rose over 2% after announcing an agreement to acquire the entire issued share capital of DFS Cotai Limitada and related business assets from DFS Group, which is ultimately owned by LVMH [3] - Weisheng Holdings (03393) increased over 5% following a visit from the Hungarian ambassador, discussing cooperation opportunities in the energy digitalization sector [3] Group 4 - Bolecon Vision Cloud-B (02592) fell over 6%, hitting a new low since its listing, after announcing plans for clinical trials of its eye drop product for treating myopia, with the application for clinical trials submitted in December 2025 [4] - Jiaxin International Resources (03858) surged over 12%, currently up 10.65%, as tungsten concentrate prices rose significantly, reflecting a 124% increase since the beginning of the year [4] Group 5 - Aerospace Holdings (00031) dropped over 14% after issuing a profit warning, expecting a net loss of approximately HKD 270 million to 290 million for the year ending December 31, 2025, compared to a loss of HKD 83.85 million in 2024 [5] Group 6 - U.S. oil stocks saw a general increase, with Occidental Petroleum (OXY.US) up 2.06% and Chevron (CVX.US) up 1.42%, as analysts predict Brent crude prices could reach an average of $130 per barrel in Q2 and Q3 if energy infrastructure is attacked [6] - Tesla (TSLA.US) fell 3.18% following an investigation by the NHTSA into its "Full Self-Driving" system due to multiple accidents [6] Group 7 - Gold and silver stocks initially experienced a sharp decline but later rebounded, with Gold Fields (GFI.US) and AngloGold Ashanti (AU.US) seeing reduced losses after significant drops in spot gold and silver prices [7] - Alibaba (BABA.US) fell over 7% after reporting Q3 revenue of RMB 28.4843 billion, a 2% year-on-year increase, but a 67% decline in adjusted net profit [7]

Core Insights - The "14th Five-Year Plan" has significantly advanced the biopharmaceutical industry, with a notable increase in the number of approved innovative drugs, rising from 11 in 2015 to 92 in 2024, and a 42% share of domestic innovative drugs [1] - The "15th Five-Year Plan" positions biopharmaceuticals as a new pillar industry, emphasizing the need for a collaborative development mechanism among healthcare, medical insurance, and pharmaceuticals [1] - The healthcare sector is transitioning from a focus on system construction to a quality-driven approach, emphasizing collaborative governance and a health-centered service model [2] Healthcare Sector - The "15th Five-Year Plan" marks a critical phase for China's healthcare, shifting from scale expansion to a focus on quality and foundational strengthening [2] - The "Three Medical Linkages" strategy is evolving towards systematic collaborative governance, exemplified by the Sanming model [2] Medical Insurance Sector - The acceleration of provincial-level coordination in medical insurance is expected to enhance fund utilization efficiency and address structural issues within the insurance system [3] - The provincial coordination system aims to redistribute surplus funds from economically developed areas to support regions facing financial challenges, thereby addressing structural imbalances [3] Pharmaceutical Sector - The national policy framework is fostering original innovation and high-quality development in the pharmaceutical industry, with a record number of new drug approvals and increased global competitiveness [4] - The industry is witnessing a shift towards domestic alternatives in high-end medical devices and life sciences, alongside the integration of AI technology to enhance research and service capabilities [4]

Core Viewpoint - The Beijing Stock Exchange (BSE) has reached a significant milestone with 300 listed companies, marking a 3.7 times increase in company numbers since its inception in November 2021, and a total market capitalization of approximately 900 billion yuan [1][4]. Group 1: Market Growth and Performance - The BSE has shown remarkable growth over four years, with the number of listed companies increasing from 81 to 300 and total market capitalization rising from under 300 billion yuan to around 900 billion yuan [4]. - In 2025, 63% of the 293 companies that reported earnings achieved revenue growth, with three companies experiencing revenue increases exceeding 100% [5]. - The average research and development intensity among the 300 listed companies exceeds 5%, with total fundraising surpassing 60 billion yuan, primarily directed towards R&D and capacity expansion [5]. Group 2: New Listings and Industry Focus - In 2026, 12 new companies were listed on the BSE, with a strong emphasis on high-end equipment, artificial intelligence, new materials, biomedicine, and industrial software [7]. - Over 70% of the new listings are classified as national-level specialized and innovative "little giants," showcasing a focus on cutting-edge technology and niche market leadership [7]. - The first-day stock price increases for new listings predominantly fell within the 100% to 200% range, indicating a robust market response and improved investor confidence [7]. Group 3: Future Outlook and Strategic Recommendations - The increase to 300 listed companies represents not only growth but also a new starting point for the BSE, emphasizing the need for continued reform and optimization of the market ecosystem [9][11]. - Experts suggest that the BSE should enhance its appeal to quality companies and improve market liquidity by potentially introducing an ETF and accelerating the implementation of reform measures [10]. - The BSE aims to differentiate itself by focusing on serving innovative small and medium-sized enterprises, ensuring a sustainable growth trajectory and a supportive market environment [10][11].

Group 1: Company Overview and Leadership - The meeting was held on March 17, 2026, in Shanghai, with key personnel including Chairman Zhang Junzheng and Vice General Manager Wang Shigang [2] - The presentation covered the development history of the company and an overview of its two main business segments [2] Group 2: PVP Product Insights - Current PVP product prices are low, but future price recovery is expected as the industry undergoes capacity clearing and consolidation [3] - The company plans to increase PVP production capacity by 15,000 tons, aiming for a total capacity of over 20,000 tons per year [3] - The current capacity utilization rate for PVP is high, aligning well with market demand [3] - The company is focusing on optimizing its product structure to increase the proportion of high-end products, which is expected to improve gross margins [3] Group 3: Raw Material and Market Conditions - The core raw material for the company's products, BDO, has remained stable with slight fluctuations since 2026, without significant price increases [3] - Rising oil prices have not yet impacted the pricing of the company's related products [3] Group 4: Investment in Biopharmaceuticals - The company has invested in five pharmaceutical-related entities, with key products under development including EAL® for liver cancer and CAR-T therapies [4][5] - Strategic cooperation is underway with Huada Biotech for the construction of a CAR-T drug production facility with an annual capacity of 8,000 to 10,000 doses [5] Group 5: Profit Distribution and Shareholder Returns - From 2022 to 2024, the company achieved a cumulative net profit of approximately 20.24 billion CNY, with cash dividends totaling about 11.34 billion CNY [5] - The cash dividend amount over the past three years accounted for approximately 89.15% of the net profit during the same period [5] - The company is committed to maintaining a high dividend payout ratio while balancing long-term development and operational funding needs [5]

1. Report Industry Investment Rating - No relevant information provided 2. Core View of the Report - The main contracts of coking coal and coke rose slightly in the night session yesterday, and the total open interest of coking coal was basically flat compared with the previous period. Last week, the coking coal production continued to increase, and the customs clearance volume of Mongolian coal also increased significantly, indicating pressure on the supply side of coking coal. Due to the impact of environmental protection restrictions, the hot metal production continued to decline, but with the end of environmental protection restrictions and the promotion of resumption of work and production, it is expected that the hot metal production will significantly rebound in the future. The increase in the listing volume and trading volume of coking coal last week also proves the current rigid demand resilience, so there is no need to be overly pessimistic about the future trend. The future focus should be on the trend of hot metal production, mine operation, and geopolitical situation [2] 3. Summary by Relevant Catalogs Futures Price and Trading Volume - **Price Changes**: The closing prices of coking coal futures contracts on different delivery dates changed compared to the previous two days. For example, the 1 - month contract decreased by 6.5 to 1475.5, with a decline of -0.44%; the 5 - month contract decreased by 5.0 to 1176.0, with a decline of -0.42%; the 9 - month contract increased by 1.5 to 1282.0, with an increase of 0.12% [2] - **Trading Volume and Open Interest**: The trading volume of the 5 - month contract was 673152, and the open interest was 391077. The open interest of the 1 - month contract decreased by 49, while that of the 9 - month contract increased by 1386 [2] - **Price Spreads**: The price spreads between different contracts also changed. For example, the 1 - 5 month spread increased by 306 to 240, and the 5 - 9 month spread increased by 2.5 to -79.5 [2] Spot Price - **Coal Types and Prices**: The current prices of low - sulfur main coking coal in Linfen (ex - factory price) is 3711, the port pick - up price of Mongolian No. 5 main coking coal is 1210, and the prices of other coal types in different regions are also provided, such as the Tangshan first - grade coke price is 1800 [2] - **Price Changes**: The price of low - sulfur main coking coal in Taiyuan (railway siding price) increased by 44, while the prices of other coal types remained unchanged [2] Policy Information - The National Development and Reform Commission has launched a new batch of 13 landmark major foreign - funded projects with a planned investment of 13.4 billion US dollars. The projects are mainly concentrated in manufacturing fields such as electronics, chemicals, automobiles, and machinery, and for the first time, logistics projects are included in the list, while continuing to support R & D center projects in fields such as biomedicine [2]

Market Overview - The Hong Kong stock market continued its upward trend, with the Hang Seng Index and the Hang Seng China Enterprises Index closing at 26,025.42 points and 8,835.50 points, respectively, up by 0.6% and 0.1% [1] - Market turnover was HKD 240.4 billion, a decrease of 10.4% from the previous day's HKD 268.3 billion, indicating cautious sentiment among some investors [1] - In sector performance, composite enterprises, industrial, and financial indices rose by 2.0%, 1.7%, and 1.1%, while telecommunications, consumer staples, and energy sectors fell by 0.1%, 0.2%, and 0.7% [1] U.S. Market Performance - The U.S. stock market saw a decline, with the Dow Jones Industrial Average closing at 46,225 points, down by 1.6% [2] - The Hang Seng Index futures closed at 25,479 points, indicating a discount of 546 points, suggesting pressure on the Hong Kong market today [2] Macroeconomic Dynamics - The U.S. Federal Funds Rate remains unchanged at 3.5%-3.75%, aligning with market expectations [3] - The U.S. Producer Price Index (PPI) for February increased by 3.4% year-on-year, surpassing January's 2.9% and market forecasts of 2.9% [3] - Factory orders in the U.S. rose by 0.1% month-on-month in February, an improvement from January's -0.4%, consistent with market predictions [3] Automotive Sector Insights - Geely Automobile (175 HK) reported a 39.0% year-on-year increase in sales for 2025, with total revenue up by 25.1% and a core net profit of RMB 14.41 billion, reflecting a 36% increase [4] - The company plans a dividend payout ratio of approximately 29%, with a year-on-year increase of 51% in the dividend per share [4] - Geely's sales target for 2026 is set at 3.45 million units, a 14% increase year-on-year, with capital expenditure expected to decrease from RMB 17.9 billion to RMB 16 billion [4] Healthcare Sector Developments - The Hang Seng Healthcare Index rose by 1.1%, with Rongchang Biopharmaceutical (9995 HK) seeing a 7.4% increase in stock price following the announcement of multiple original research results at the 2026 EAU [4] - Junshi Biosciences (1877 HK) also experienced a stock price increase of 5.8% after reporting a reduction in losses for 2025 [4] New Energy and Utilities Sector Performance - The new energy and utilities sector generally saw gains, except for photovoltaic and nuclear energy [5] - Electric equipment stocks performed well, with Weisheng Holdings (3393 HK) rising by 8.6% after securing a supply contract worth approximately RMB 180 million with Brazil's CEMIG [5] - The thermal power sector also experienced increases, with Huaneng International (902 HK), Datang Power (991 HK), and Huadian International (1071 HK) rising between 0.5% and 2.3% [5]

Investment Rating - The report maintains an "Overweight" rating for the biopharmaceutical and chemical pharmaceutical sectors [6]. Core Insights - The Chinese innovative drug sector is at the beginning of a long cycle, with continuous global output of high-quality assets from Chinese companies. The potential of these assets is not fully reflected in A/H share pricing, leading to a recommendation for the innovative drug sector [1]. - The number and value of business development (BD) deals in the Chinese innovative drug industry have reached record highs in 2023, with 45 BD deals completed (+73% year-on-year) and a total disclosed amount of $57.5 billion (+135% year-on-year) [2]. - The report highlights a significant valuation gap between A/H shares and US stocks for similar innovative drug assets, indicating that A/H shares are systematically undervalued [4]. Summary by Sections Business Development Trends - The report notes that the Chinese innovative drug sector has achieved a global market share of approximately 20% in the number of BD projects and around 75% in the disclosed amount [2]. - There is a high predictability of continued growth in BD activities, driven by increasing interest from multinational corporations (MNCs) and private equity (PE) firms in Chinese assets [2]. Cash Flow Contributions - The report emphasizes that platform companies in China are expected to generate sustainable cash flows through ongoing BD activities, which have not been adequately valued in the market [3]. - It is projected that significant BD deals (with upfront payments exceeding $500 million) will contribute to continuous cash flow growth for companies like Heng Rui Medicine, Shiyao Group, and others [3]. Valuation Comparisons - The report compares the valuations of similar assets in A/H shares and US markets, revealing that Chinese innovative drug companies are undervalued relative to their US counterparts [4][19]. - Specific case studies illustrate the valuation discrepancies, such as between MSD and Kelun Biotech, and Insmed and Haizhi Pharmaceutical, highlighting the potential for significant upside in A/H share valuations [19][22]. Investment Recommendations - The report recommends focusing on large pharmaceutical and biopharmaceutical companies with sustained BD capabilities, including Heng Rui Medicine, Shiyao Group, and others [5]. - Companies that have completed large BD deals are expected to benefit from ongoing milestone cash flows, with specific recommendations for companies like Kelun Biotech and Rongchang Biopharmaceutical [5]. Target Prices and Market Outlook - Target prices for recommended stocks are provided, with specific price targets for companies such as Shiyao Group at HKD 19.25 and Heng Rui Medicine at HKD 98.43, indicating a bullish outlook for these stocks [26].